NuView gains rights to imaging agent from Philadelphia university
NuView Radiopharmaceuticals has executed an agreement with Thomas Jefferson University in Philadelphia for the exclusive distribution and commercialization rights for a tumor-specific imaging agent that assists in the diagnosis of breast and prostate tumors.
NuView said it also intends to sponsor research at Jefferson to further develop the technology.
Matthew Thakur, MD, director of radiopharmaceutical research and professor of radiology and radiation oncology at Jefferson Medical College at Thomas Jefferson, has demonstrated the potential for radiopharmaceutical imaging of breast, prostate and lung cancers, according to the Park City, Utah-based NuView. Thakur and his team have been studying the binding of the small molecule peptide PACAP to vasoactive pituitary adenylate cyclase receptors expressed in high density on tumors, the company said.
The company also said that further studies of testing imaging techniques are also underway with patients at the Moores Cancer Center at University of California, San Diego (USCD) Medical Center in San Diego. "If the Jefferson technology works as well as we hope, it will usher in a whole new generation of diagnostic PET tracers for imaging breast and prostate carcinoma using PET-CT or PET-MR in the future. The improved sensitivity and specificity of these new agents should lead to better treatment and improved patient outcome," said William G. Bradley, Jr., MD, PhD, and chair of radiology at UCSD.
NuView said it also intends to sponsor research at Jefferson to further develop the technology.
Matthew Thakur, MD, director of radiopharmaceutical research and professor of radiology and radiation oncology at Jefferson Medical College at Thomas Jefferson, has demonstrated the potential for radiopharmaceutical imaging of breast, prostate and lung cancers, according to the Park City, Utah-based NuView. Thakur and his team have been studying the binding of the small molecule peptide PACAP to vasoactive pituitary adenylate cyclase receptors expressed in high density on tumors, the company said.
The company also said that further studies of testing imaging techniques are also underway with patients at the Moores Cancer Center at University of California, San Diego (USCD) Medical Center in San Diego. "If the Jefferson technology works as well as we hope, it will usher in a whole new generation of diagnostic PET tracers for imaging breast and prostate carcinoma using PET-CT or PET-MR in the future. The improved sensitivity and specificity of these new agents should lead to better treatment and improved patient outcome," said William G. Bradley, Jr., MD, PhD, and chair of radiology at UCSD.